Johns Manville Trust: $5+ Billion Paid, 1 Million Claims Processed, America's First Asbestos Bankruptcy Trust (1988)

Johns Manville Trust Quick Facts
	America's oldest and largest asbestos trust fund
Payment Rate	5.1% (February 2021 — current)
Meso Scheduled Value	$350,000
Actual Meso Payout	~$17,850
Total Assets (2024)	$619.9 Million
Total Claims Paid	~1 Million
Total Distributed	$5+ Billion
Trust Established	November 28, 1988
Bankruptcy Filed	August 26, 1982
Administrator	CRMC (Falls Church, VA)
	Check Your Eligibility

Executive Summary

The Johns Manville Trust is the oldest and largest asbestos bankruptcy trust in the United States, having processed nearly one million claims and distributed over $5 billion in compensation since its establishment in 1988. Originally funded with $2.5 billion, the trust currently maintains $619.9 million in assets and pays 5.1% of scheduled claim values since its February 2021 adjustment. Johns Manville Corporation, founded in 1858 and once the world's largest asbestos manufacturer, filed for bankruptcy protection on August 26, 1982, in a landmark case that created the legal framework for all subsequent asbestos trusts. Mesothelioma victims exposed to Johns Manville's signature Transite products, Kaylo insulation, or any of the company's thousands of asbestos-containing materials can file claims with this trust while simultaneously pursuing additional compensation through lawsuits and other trust funds.

Johns Manville's dominance in the American asbestos market means the company's products appeared in virtually every industrial, commercial, and residential construction project from the 1920s through the 1970s. The company manufactured over 2,000 asbestos-containing products including pipe insulation, building materials, brake linings, roofing shingles, cement pipes, and industrial textiles. Insulation Workers, Boilermakers, Plumbers and Pipefitters, and Construction Workers encountered Johns Manville materials daily on jobsites across America. Naval personnel working at facilities like Norfolk Naval Shipyard, Portsmouth Naval Shipyard, and Brooklyn Navy Yard were exposed to Kaylo insulation and other JM products installed throughout ships during World War II and the Cold War era.

The Johns Manville bankruptcy case established the Section 524(g) trust framework that all subsequent asbestos bankruptcies would follow. This legal structure allows companies to reorganize while setting aside dedicated funds for current and future asbestos victims. The Johns Manville Trust continues operating under court supervision, with CRMC (Claims Resolution Management Corporation) administering claims and making quarterly payments to approved claimants. While the 5.1% payment percentage ranks among the lowest of major trusts, the $350,000 scheduled value for mesothelioma claims still results in approximately $17,850 per claim—a meaningful component of comprehensive compensation strategies that typically involve claims against multiple trusts.

Because Johns Manville products were so widespread, most mesothelioma victims with occupational asbestos exposure will qualify for this trust regardless of their specific industry or jobsite. The trust maintains detailed product databases and accepts various forms of exposure evidence, including employment records, union documentation, co-worker affidavits, and product identification evidence. Veterans should note that Johns Manville Trust payments do not reduce VA disability compensation—both can be collected simultaneously under federal law. Experienced mesothelioma attorneys coordinate Johns Manville claims with filings at other trusts like Owens Corning Trust, Pittsburgh Corning Trust, and WR Grace Trust to maximize total recovery.

Why This Matters

Despite having one of the lowest payment percentages among major trusts at 5.1%, Johns Manville remains critically important for mesothelioma victims because the company's products were ubiquitous in American construction, shipbuilding, and industrial applications from the 1920s through the 1970s. Most workers with significant asbestos exposure encountered at least one Johns Manville product, making this trust a near-universal component of comprehensive compensation recovery strategies.

⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.

How Has the Johns Manville Trust Payment Rate Changed Over Time?

The Johns Manville Trust payment percentage has undergone multiple adjustments since its establishment in 1988, reflecting changing financial conditions, investment performance, and claims volume. Understanding this history is critical because claimants filing at different times may receive substantially different compensation for identical medical conditions.

Payment Percentage Timeline

Time Period	Payment Rate	Key Trigger
Pre-July 1990	100%	Claims paid in full on first-in, first-out (FIFO) basis; initial funding model
July 1990	FROZEN	Trust depleted assets; court imposed complete payment freeze due to claims volume exceeding projections
February 21, 1995	10%	Trust Distribution Process (TDP) established; pro rata payment system adopted following class action settlement
June 2001	5%	Downward adjustment; projected assets insufficient to maintain 10% rate
March 2008	7.5%	Increased due to favorable investment returns; triggered $365.7 million in retroactive payments to approximately 282,000 previously eligible claimants
August 2014	6.25%	Reduction based on updated actuarial projections and asset review
November 2016	5.1%	Adjustment following comprehensive review of trust liabilities and long-term sustainability
April 28, 2020	4.3%	Significant reduction due to COVID-19 pandemic; sharp decline in equity markets reduced trust asset values
February 15, 2021	5.1%	Restoration to previous level; investment asset values recovered; current rate as of 2026

Understanding Payment Rate Changes

The Johns Manville Trust employs a sophisticated mechanism for adjusting payment percentages to balance current claimants' needs with long-term trust solvency. The Trust Distribution Process (TDP), established in February 1995, requires the Board of Trustees to conduct periodic reviews—at minimum every three years—of the trust's projected assets and liabilities.

A payment rate change is implemented only when the Board of Trustees, the Selected Counsel for Beneficiaries (SCB), and the Legal Representative of Future Claimants mutually concur that adjustment is necessary. This tripartite approval mechanism ensures that changes reflect genuine financial necessity rather than arbitrary decisions, protecting both current and future claimants.

"The payment percentage tells only part of the story. When we see the rate drop, it means the trustees are making difficult decisions to ensure the trust remains solvent for the next generation of claimants. Our job is to maximize what our clients receive within that system." — Paul Danziger, Founding Partner, Danziger & De Llano

Maximum Annual Payment Provision

In January 2012, the Board of Trustees amended the TDP to include a Maximum Annual Payment (MAP) provision, a critical safeguard for long-term trust sustainability. The MAP limits the total amount the trust may disburse in any given calendar year based on conservative projections of investment income and claim processing capacity.

When accumulated pending claims would cause annual payments to exceed the MAP, the trust continues processing claims in first-in, first-out order but carries unpaid claims forward to the following year. This mechanism prevents depletion of assets in high-volume years while ensuring orderly, predictable claim resolution. Claimants whose claims are carried forward do not lose their position in the queue—they maintain their FIFO priority and receive their settlement offer at the established pro rata percentage once funds become available.

The 2024 financial data shows approximately $49.8 million in claims paid during the year, demonstrating that the MAP provision has successfully balanced claim payment with asset preservation.

What Are the Johns Manville Trust Disease Levels and Payment Amounts?

The Johns Manville Trust uses a standardized disease classification system (disease levels) to establish scheduled liquidated values for different asbestos-related conditions. This system provides claimants with predictable, documented compensation levels while accelerating claim processing. Claimants with straightforward cases can accept their scheduled value through expedited review, while those with exceptional circumstances may pursue individual evaluation.

Current Disease Levels and Scheduled Values

Disease Level	Medical Category	Scheduled Value	Current Payout @ 5.1%
Level VIII	Mesothelioma (all types)	$350,000	~$17,850
Level VII	Lung Cancer (two or more conditions)	$95,000	~$4,845
Level VI	Lung Cancer (single condition)	Individual Review	~$2,040 (average)
Level V	Other Cancer	$45,000	~$2,295
Level IV	Severe Asbestosis	$95,000	~$4,845
Level III	Asbestosis/Pleural Disease (advanced)	$25,000	~$1,275
Level II	Asbestosis/Pleural Disease (mild-moderate)	$12,000	~$612

Understanding Disease Level Classification

The disease level system reflects the severity and functional impairment associated with different asbestos-related conditions:

Mesothelioma (Level VIII): All forms of mesothelioma—pleural, peritoneal, and pericardial—receive the highest scheduled value. The category reflects mesothelioma's uniformly fatal prognosis and the established causation link to asbestos exposure.

Lung Cancer (Levels VI-VII): Classification depends on whether the claimant has asbestosis or other asbestos-related conditions in addition to lung cancer. Level VII reflects multiple concurrent conditions, while Level VI indicates lung cancer as the primary diagnosis.

Other Cancers (Level V): Includes cancers with established or probable asbestos causation (laryngeal cancer, colorectal cancer, ovarian cancer) that do not meet the stricter criteria for direct asbestos causation but have documented association with asbestos exposure.

Severe Asbestosis (Level IV): Reflects extensive lung parenchymal disease with significant functional impairment, typically requiring oxygen supplementation or demonstrating FEV1 reduction exceeding 50%.

Asbestosis/Pleural Disease (Levels II-III): Distinguish between mild-to-moderate pleural thickening or plaques (Level II) and more advanced asbestosis with functional impairment (Level III). Both categories may include pleural effusions.

Individual Review Process

Claimants may pursue individual review for any disease level, particularly when circumstances suggest compensation beyond the scheduled value:

Medical condition more severe than typical for the disease level
Substantial documented economic losses (lost wages, medical expenses, vocational rehabilitation costs)
Multiple comorbid conditions
Age and life expectancy factors
Exceptional exposure history with multiple Johns Manville products

Individual review typically requires 4-12 months for completion but may result in compensation exceeding the scheduled amount. An experienced mesothelioma attorney can evaluate whether individual review is warranted based on specific circumstances.

"Disease levels provide a baseline, but every case has unique aspects. We review each client's medical evidence and exposure history to determine whether seeking individual review justifies the additional processing time." — Rod De Llano, Senior Attorney, Danziger & De Llano

What Is the Current Financial Health of the Johns Manville Trust?

The Johns Manville Trust maintains robust financial health, with total assets of $619.9 million as of December 31, 2024, according to audited financial statements filed with the U.S. Bankruptcy Court, Southern District of New York. Understanding the trust's financial position provides important context for the sustainability of claim payments and the likelihood of future rate adjustments.

2024 Audited Financial Position

Financial Metric	Amount
Total Assets	$619,950,547
Cash and Cash Equivalents	$11,600,000
Accrued Interest and Dividends	$2,525,258
Net Claimants' Equity	$556,862,683
Restricted Funds (Legal Contingencies)	$42,300,000
Unrestricted Investment Assets	$574,490,319

Investment Portfolio Composition

The trust maintains a diversified investment portfolio balancing growth potential with capital preservation:

Asset Class	Fair Market Value	Percentage
U.S. Equities	$309,800,000	~50%
International Equities	$60,900,000	~10%
Corporate and Other Debt	$126,500,000	~20%
U.S. Government Obligations	$108,100,000	~17%
Cash Equivalents	$11,600,000	~2%
Total Investment Portfolio	$616,900,000	100%

The portfolio's equity weighting (approximately 60% in stocks) reflects the trust's long-term investment horizon and the need for growth to outpace inflation and claim increases. U.S. Government obligations and corporate debt provide stability and regular income, while international diversification reduces concentration risk.

Annual Operations Summary

Category	2024	2023
Net Investment Income	$78,689,462	$83,605,147
Personal Injury Claims Settled	$52,095,788	$55,367,846
Claims Paid (Cash Disbursed)	$49,777,753	$55,461,215
Administrative Operating Expenses	$3,695,343	$3,213,333
Federal Income Tax Provision	$8,819,606	$5,736,602
Year-End Net Claimants' Equity	$556,862,683	$542,403,681

Long-Term Sustainability Analysis

The trust's annual net investment income ($78.7 million in 2024) significantly exceeds annual claims disbursements ($49.8 million), providing a cushion for payment sustainability. The trust's financial projections, reviewed annually by independent auditors, indicate a substantial probability of remaining solvent for 10-20+ years at current payment rates.

However, it is important to understand that the Johns Manville Trust is classified legally as a "limited fund"—meaning the trust's estimated future assets are projected to be insufficient to pay all claims in full at 100% eventually. This classification has prompted the tripartite rate-adjustment mechanism and drives the conservative financial management policies that have enabled the trust to operate continuously since 1988 without missing a scheduled payment.

Cumulative Trust Payouts Since Establishment:

Total claims liquidated: 1,013,971
Total amount distributed: Approximately $5.26 billion (pro rata adjusted, from Nov 28, 1988 through Dec 31, 2024)
Average payout per claim: Approximately $5,186

⚠️ Important Context: While the trust is financially sound, the declining payment percentage from 100% (pre-1990) to 5.1% (current) reflects the mathematical reality of fixed assets serving unlimited claims. Early claimants received substantially higher settlement values. Individuals diagnosed with asbestos disease should file claims promptly to avoid further percentage reductions.

How Does CRMC Process Johns Manville Trust Claims?

The Claims Resolution Management Corporation (CRMC) was established in December 1998 as a wholly owned subsidiary of the Johns Manville Trust. This specialized corporation handles all aspects of claim intake, evaluation, and settlement, providing a streamlined, professional claims processing operation.

CRMC Background and Operations

CRMC began operations on January 1, 1999, initially located in Fairfax, Virginia, and subsequently relocated to Falls Church, Virginia, where it maintains its current office (current office lease expires September 30, 2028). As a specialized claims administrator, CRMC operates under the Trust Distribution Process (TDP) guidelines established by the Johns Manville Trust and approved by the bankruptcy court.

Beyond administering Johns Manville Trust claims, CRMC also provides administrative services to other asbestos trusts, with revenue from third-party trust administration credited against CRMC's operating expenses, reducing costs to Johns Manville claimants.

Claim Intake and Processing Overview

CRMC accepts claims through two channels:

E-Filers (Electronic Submission):

Claims and supporting documentation submitted electronically
Faster initial processing and acceptance/denial determination
Claimants receive electronic settlement offers
Electronic acceptance available (no physical signatures required)
Recommended for claimants with well-organized documentation

Paper Filers (Traditional Submission):

Claims submitted on physical paper forms with supporting documents
Standard processing timeline applies
Settlement offers made via mail
Claimants return signed release agreements for final settlement

FIFO Queue and Settlement Processing

All claims are processed in first-in, first-out (FIFO) order, regardless of submission method or disease severity. This means a claim filed earlier receives a settlement offer before a claim filed later, even if the later claim involves mesothelioma and the earlier claim involves mild asbestosis.

Once a claim reaches the front of the FIFO queue, CRMC issues a formal settlement offer at the current pro rata percentage (currently 5.1% of the scheduled liquidated value for the claimant's disease level). The offer specifies:

Claimant's name and identifying information
Disease level classification
Scheduled liquidated value
Pro rata calculation and current payment amount
Settlement release language
Acceptance deadline (360 days from offer issuance)

Outstanding Offers and Reinstatement

An outstanding settlement offer remains valid for 360 days (approximately 12 months) from issuance. If a claimant does not accept within this period, the offer expires and the claim returns to the FIFO queue.

However, claims are not lost—they may be reinstated within 2 years of expiration by submitting a reinstatement request to CRMC. Once reinstated, the claim returns to its original position in the FIFO queue (not to the end) and receives a new settlement offer. Claims cannot be reinstated after 2 years have elapsed from the original offer's expiration.

Claimants sometimes allow offers to expire strategically, hoping for a future payment percentage increase before reinstatement. While this is legally permissible, it carries risk: if the payment percentage decreases further, the reinstated offer reflects the lower rate.

Required Documentation

CRMC requires complete medical and exposure documentation to process claims:

Pathology Report: Definitive diagnosis from board-certified pathologist confirming asbestos-related disease
Medical Records: Treating physician notes, imaging studies (chest X-rays, CT scans), pulmonary function testing results
Employment History: Complete work history with employers, job titles, dates of employment, locations worked
Product Identification: Documentation of Johns Manville product exposure (product names, brands such as Transite, Kaylo, or generic descriptions)
Witness Affidavits: Written statements from co-workers, family members, or others with direct knowledge of claimant's exposure
Death Certificate: Required for wrongful death claims

Incomplete claims are returned to claimants with requests for additional information. Processing cannot proceed until documentation is complete and meets CRMC's established standards.

"CRMC processes thousands of claims annually and has established clear standards for what documentation meets evidentiary requirements. Our role is assembling the strongest possible documentation package to ensure claims move through the system without delays or rejection." — Larry Gates, Client Advocate, Danziger & De Llano

How Do You File a Claim with the Johns Manville Trust?

The Johns Manville Trust offers two claim review options:

Expedited Review (Faster, Fixed Amount)

Processing time: Typically 90 days to 4 months
Fixed payment based on disease category
No individual assessment of case specifics
Best for: Straightforward cases with clear documentation

Individual Review (Longer, Potentially Higher)

Processing time: 4-12 months or longer
Case-specific evaluation
May receive higher compensation based on:
- Severity of disease
- Economic losses (lost wages, medical costs)
- Extent of documented exposure
Best for: Complex cases or exceptional circumstances

Required Documentation:

Pathology report confirming diagnosis
Medical records and imaging studies
Employment history with dates and locations
Product identification evidence
Witness affidavits from co-workers (when available)
Death certificate (for wrongful death claims)

Which Occupations Had the Highest Johns Manville Exposure?

Johns Manville products were used across virtually every American industry, but certain occupations faced particularly intense exposure:

Highest Risk Occupations:

Shipyard workers (Kaylo and marine insulation)
Insulation installers and removers
Construction Workers
Boilermakers and pipefitters
Electricians
HVAC technicians
Brake mechanics (brake linings)
Roofers (shingles and roofing materials)
Factory workers at JM facilities

Industries with Extensive JM Product Use:

Naval shipbuilding (WWII through Vietnam era)
Commercial construction
Power generation plants
Oil refineries
Chemical plants
Automotive manufacturing
Railroad industry

"Growing up in Pasadena near the refineries, we saw Johns Manville products everywhere. These companies knew for decades that their insulation was killing workers, but they kept selling it anyway. Every claim we help file honors the workers who deserved better." — Larry Gates, Client Advocate, Danziger & De Llano

Can You File Both a Trust Claim and a Lawsuit?

Yes. Filing a Johns Manville Trust claim does not prevent you from pursuing:

Other Trust Fund Claims: Most mesothelioma victims qualify for 5-15 different trust funds
Lawsuits Against Solvent Companies: Companies that haven't declared bankruptcy can still be sued directly
VA Benefits: Veterans can claim VA disability benefits alongside trust compensation
Workers' Compensation: In most states, trust fund payments don't affect workers' comp eligibility

⚠️ Coordination Required: Some states require disclosure of trust fund payments during lawsuit discovery. Experienced asbestos attorneys coordinate these filings to maximize total recovery while complying with all legal requirements.

What Is the Future Outlook for the Johns Manville Trust?

The Johns Manville Trust is projected to remain operational for 10-20+ years based on current payment rates and claim projections. Key considerations:

Trust Sustainability:

Current assets: $619.9 million (December 2024)
Annual net investment income: $78.7 million (2024)
Annual claims paid: $49.8 million (2024)
Payment percentage adjusted to preserve long-term solvency
Approximately 10-20 year projected sustainability at current levels

Ongoing Concerns:

Document destruction policies may affect future claims
Payment percentages have trended downward over time (100% pre-1990 to 5.1% current)
Claimants should file without delay to preserve rights

The trust maintains detailed actuarial projections updated annually by independent auditors. While the trust is financially sound, the mathematical reality of a fixed fund serving unlimited claims means that aggressive, early filing remains the best strategy for maximizing compensation.

Johns Manville Corporate History

Johns Manville Corporation was founded in 1858 when Henry Ward Johns established the H.W. Johns Manufacturing Company in New York City. The company specialized in asbestos roofing materials and insulation. In 1901, the H.W. Johns Manufacturing Company merged with the Manville Covering Company (founded 1886) to create the H.W. Johns-Manville Company, which was renamed Johns-Manville Corporation in 1926.

Johns-Manville grew to become the world's largest asbestos products manufacturer by the 1970s, with operations spanning manufacturing facilities, mining operations, and international subsidiaries across 12+ countries. The company went public on the New York Stock Exchange in 1927 and was added to the Dow Jones Industrial Average on January 29, 1930.

Under aggressive management, Johns-Manville expanded through acquisitions, vertical integration (acquiring asbestos mines in Quebec and Arizona to secure 50-75 years of raw material supply), and product diversification. By the 1970s, the company manufactured over 2,000 asbestos-containing products, ranging from pipe insulation and building materials to automotive brake linings and commercial roofing systems.

By August 1982, facing approximately 16,500 pending asbestos-related lawsuits and consultants' estimates of 32,000+ additional cases over the following 20 years, Johns-Manville filed for Chapter 11 bankruptcy protection. The bankruptcy filing, at that time the largest in U.S. history, was approved unanimously by the company's board of directors.

Johns Manville's Knowledge of Asbestos Dangers

Internal company documents and depositions reveal that Johns Manville possessed knowledge of asbestos health hazards decades before implementing adequate warnings or product modifications:

1935: Company executives wrote that the company's interests would be served by having asbestosis receive "minimal publicity." The Simpson-Brown correspondence documented the statement: "The less said about asbestos, the better off we are."

1948-1952: Dr. Kenneth Smith, the company's medical director, recommended suppressing X-ray results showing asbestosis in workers and recommended warning labels on products. Company management rejected the warning label recommendation as a "business decision."

1929-1933: Johns-Manville settled lawsuits with 11 employees suffering from asbestos-related conditions on the condition that the plaintiff's lawyer would not bring new actions against the company, effectively using secrecy agreements to suppress legal information about asbestos dangers.

1934: Officials at Johns-Manville and other asbestos manufacturers rewrote an article about asbestos worker diseases, written by a Metropolitan Life doctor, to minimize the dangers of asbestos dust.

The company's internal suppression of health information, despite simultaneous knowledge of asbestos dangers, became a central issue in subsequent asbestos litigation and contributed to the bankruptcy filing's legal characterization as a response to massive liability for fraudulent concealment.

Get Help Today

If you or a loved one was exposed to Johns Manville products and has been diagnosed with mesothelioma, you may be eligible for compensation from this trust and others. Experienced mesothelioma attorneys can identify all qualifying trusts, prepare proper documentation, and coordinate filings to maximize your total recovery.

Free, Confidential Case Evaluation

Call (866) 222-9990 or visit dandell.com/contact-us

No upfront fees • Experienced representation • National practice